First Time Loading...

Societal CDMO Inc
NASDAQ:SCTL

Watchlist Manager
Societal CDMO Inc Logo
Societal CDMO Inc
NASDAQ:SCTL
Watchlist
Price: 1.1 USD Market Closed
Updated: May 16, 2024

P/E
Price to Earnings

-8.7
Current
-4.9
Median
23.4
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-8.7
=
Market Cap
115.3m
/
Net Income
-13.3m
All Countries
Close
Market Cap P/E
US
Societal CDMO Inc
NASDAQ:SCTL
115.3m USD -8.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
748B USD 121.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 45.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
US
Johnson & Johnson
NYSE:JNJ
367.4B USD 9.5
US
Merck & Co Inc
NYSE:MRK
333.6B USD 144.7
UK
AstraZeneca PLC
LSE:AZN
188.8B GBP 37.8
CH
Roche Holding AG
SIX:ROG
187.2B CHF 16.3
CH
Novartis AG
SIX:NOVN
181.6B CHF 11.5
US
Pfizer Inc
NYSE:PFE
162.7B USD -526.6
Earnings Growth
US
Societal CDMO Inc
NASDAQ:SCTL
Average P/E: 55.3
Negative Multiple: -8.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
121.9
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.6
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-20%
US
Merck & Co Inc
NYSE:MRK
144.7
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.8
168%
CH
Roche Holding AG
SIX:ROG
16.3
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -526.6
680%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-12.6
2-Years Forward
P/E
-17.9
3-Years Forward
P/E
N/A

See Also

Discover More